KPTI insider transaction filings
Karyopharm Therapeutics Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen KPTI transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings by 2 insiders — 208 shares, $1,380 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 189 shares @ $7.10 ($1,342) by Poulton Stuart, filed 2026-07-30.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Poulton Stuart — EVP, Chief Development Officer | 1 | — | 1 leg · 189 sh · $1,342 | — |
| Abate Kristin — Chief Accounting Officer | 1 | — | 1 leg · 19 sh · $38 | — |
Recent Form 4 filings — Karyopharm Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Abate Kristin — Chief Accounting Officer | Sale (S): 19 @ $2.02 | EDGAR |
| 2026-07-30 | 4 | Poulton Stuart — EVP, Chief Development Officer | Sale (S): 189 @ $7.10 | EDGAR |
| 2026-05-26 | 4 | Su Zhen — Director | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-05-26 | 4 | Oliger Christy J. — Director | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-05-26 | 4 | Schor Chen — Director | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-05-26 | 4 | Greene Barry E — Director | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-05-26 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-05-26 | 4 | BOHLIN GAREN G — Director | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-05-15 | 4 | Poulton Stuart — EVP, Chief Development Officer | Grant/award (A): 896 @ $0 · Sale (S): 403 @ $9.50 | EDGAR |
| 2026-05-15 | 4 | Rangwala Reshma — EVP & Chief Medical Officer | Grant/award (A): 947 @ $0 · Sale (S): 408 @ $9.50 | EDGAR |
| 2026-05-15 | 4 | Cheng Sohanya Roshan — EVP & Chief Commercial Officer | Grant/award (A): 947 @ $0 · Sale (S): 324 @ $9.50 | EDGAR |
| 2026-05-15 | 4 | Abate Kristin — Chief Accounting Officer | Grant/award (A): 121 @ $0 · Sale (S): 53 @ $9.50 | EDGAR |
| 2026-05-15 | 4 | Paulson Richard A. — President and CEO, Director | Grant/award (A): 4,920 @ $0 · Sale (S): 2,203 @ $9.50 | EDGAR |
| 2026-05-15 | 4 | Mano Michael — EVP, CLO&Secretary | Grant/award (A): 700 @ $0 · Sale (S): 266 @ $9.50 | EDGAR |
| 2026-04-22 | 4 | Rangwala Reshma — EVP & Chief Medical Officer | Sale (S): 449 @ $8.94 | EDGAR |
| 2026-03-03 | 4 | Abate Kristin — Chief Accounting Officer | Sale (S): 559 @ $9.41 | EDGAR |
| 2026-03-03 | 4 | Poulton Stuart — EVP, Chief Development Officer | Sale (S): 5,101 @ $9.41 | EDGAR |
| 2026-03-03 | 4 | Cheng Sohanya Roshan — EVP & Chief Commercial Officer | Sale (S): 4,604 @ $9.41 | EDGAR |
| 2026-03-03 | 4 | Mano Michael — EVP, CLO&Secretary | Sale (S): 3,526 @ $9.41 | EDGAR |
| 2026-03-03 | 4 | Rangwala Reshma — EVP & Chief Medical Officer | Sale (S): 5,066 @ $9.41 | EDGAR |
| 2026-03-03 | 4 | Paulson Richard A. — President and CEO, Director | Sale (S): 12,361 @ $9.41 | EDGAR |
| 2026-02-19 | 4 | Poulton Stuart — EVP, Chief Development Officer | Sale (S): 378 @ $8.63 | EDGAR |
| 2026-02-09 | 4 | Paulson Richard A. — President and CEO, Director | Grant/award (A): 81,060 @ $0 | EDGAR |
| 2026-02-04 | 4 | Macomber Lori — EVP, CFO & Treasurer | Sale (S): 1,626 @ $6.30 | EDGAR |
| 2026-02-03 | 4 | Cheng Sohanya Roshan — EVP & Chief Commercial Officer | Grant/award (A): 32,415 @ $0 | EDGAR |
| 2026-02-03 | 4 | Rangwala Reshma — EVP & Chief Medical Officer | Grant/award (A): 32,415 @ $0 | EDGAR |
| 2026-02-03 | 4 | Macomber Lori — EVP, CFO & Treasurer | Grant/award (A): 32,415 @ $0 | EDGAR |
| 2026-02-03 | 4 | Mano Michael — EVP, CLO&Secretary | Grant/award (A): 32,415 @ $0 | EDGAR |
| 2026-02-03 | 4 | Poulton Stuart — EVP, Chief Development Officer | Grant/award (A): 32,415 @ $0 | EDGAR |
| 2026-01-29 | 4 | Abate Kristin — Chief Accounting Officer | Grant/award (A): 92 @ $0 · Sale (S): 50 @ $7.03 | EDGAR |
| 2026-01-22 | 4 | Abate Kristin — Chief Accounting Officer | Sale (S): 265 @ $5.96 | EDGAR |
| 2025-10-16 | 4 | Abate Kristin — Chief Accounting Officer | Grant/award (A): 12,799 @ $0 | EDGAR |
| 2025-10-16 | 4 | Poulton Stuart — EVP, Chief Development Officer | Grant/award (A): 39,682 @ $0 | EDGAR |
| 2025-10-16 | 4 | Mano Michael — SVP, General Counsel&Secretary | Grant/award (A): 43,650 @ $0 | EDGAR |
| 2025-10-16 | 4 | Paulson Richard A. — President and CEO, Director | Grant/award (A): 114,285 @ $0 | EDGAR |
| 2025-10-16 | 4 | Cheng Sohanya Roshan — EVP & Chief Commercial Officer | Grant/award (A): 43,650 @ $0 | EDGAR |
| 2025-10-16 | 4 | Macomber Lori — EVP, CFO & Treasurer | Grant/award (A): 43,650 @ $0 | EDGAR |
| 2025-10-03 | 4 | Abate Kristin — Chief Accounting Officer | Sale (S): 362 @ $6.30 | EDGAR |
| 2025-09-16 | 4 | Paulson Richard A. — President and CEO, Director | Grant/award (A): 2,800 @ $0 · Sale (S): 1,257 @ $6.43 | EDGAR |
| 2025-09-16 | 4 | Mano Michael — SVP, General Counsel&Secretary | Grant/award (A): 612 @ $0 · Sale (S): 234 @ $6.43 | EDGAR |
| 2025-09-16 | 4 | Poulton Stuart — EVP, Chief Development Officer | Grant/award (A): 888 @ $0 · Sale (S): 401 @ $6.43 | EDGAR |
| 2025-09-16 | 4 | Rangwala Reshma — EVP & Chief Medical Officer | Grant/award (A): 945 @ $0 · Sale (S): 408 @ $6.43 | EDGAR |
| 2025-09-16 | 4 | Cheng Sohanya Roshan — EVP & Chief Commercial Officer | Grant/award (A): 945 @ $0 · Sale (S): 325 @ $6.43 | EDGAR |
| 2025-09-16 | 4 | Abate Kristin — Chief Accounting Officer | Grant/award (A): 46 @ $0 · Sale (S): 23 @ $6.43 | EDGAR |
| 2025-09-04 | 4 | Abate Kristin — Chief Accounting Officer | Sale (S): 12 @ $6.78 | EDGAR |
| 2025-07-30 | 4 | Poulton Stuart — EVP, Chief Development Officer | Sale (S): 191 @ $4.37 | EDGAR |
| 2025-07-23 | 4 | Abate Kristin — Chief Accounting Officer | Sale (S): 238 @ $4 | EDGAR |
| 2025-05-29 | 4 | Greene Barry E — Director | Grant/award (A): 4,600 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 4,600 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | BOHLIN GAREN G — Director | Grant/award (A): 4,600 (derivative) @ $0 | EDGAR |
Recent 8-K events — Karyopharm Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-18 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KPTI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →